Relationship of vascular 15-lipoxygenase induction to atherosclerotic plaque formation in rabbits.
Aortas from atherosclerotic rabbits have increased levels of 15-lipoxygenase, but the relationship between induction of this enzyme and the atherosclerotic process has not been defined. We found that dietary administration of cortisone acetate significantly suppressed atherosclerotic plaque formation in both Watanabe Heritable Hyperlipidemic (WHHL) and cholesterol-fed WHHL/NZW heterozygous rabbits. There was, however, no corresponding decrease in the elevated 15-lipoxygenase activity. In addition, the elevated 15-lipoxygenase activity in atherosclerotic rabbit aortas was uniformly distributed throughout the aorta, and was not preferentially localized in the lesions. These results indicate that induction of the 15-lipoxygenase is not necessarily causally related to plaque development, and that plaques are not the major source of the increased enzyme activity. However, the results confirm that hypercholesterolemia is a necessary condition for both atherosclerosis and 15-lipoxygenase induction, suggesting that perhaps the 15-lipoxygenase may represent a protective response to the hyperlipidemic stress. This possibility is supported by the finding that the induced 15-lipoxygenase converts linoleic acid, which is the predominant essential fatty acid in aorta, to 13-hydroxyoctadecadienoic acid (13-HODE). This compound is a chemorepellant factor for platelets, inhibits platelet thromboxane synthesis, and stimulates prostacyclin synthesis by endothelial cells.
Simon
T C
TC
Department of Biochemistry and Molecular Biology, George Washington University School of Medicine Washington, D.C. 20037.
Makheja
A N
AN
Bailey
J M
JM
D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000201:enzymology*; D001092:Arachidonate 12-Lipoxygenase / Q000378:metabolism; D001093:Arachidonate 15-Lipoxygenase / Q000096:biosynthesis*; D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D003348:Cortisone / Q000031:analogs & derivatives / Q000494:pharmacology; D004036:Diet, Atherogenic; D004195:Disease Models, Animal; D004790:Enzyme Induction; D006579:Heterozygote; D006801:Humans; D006950:Hyperlipidemia, Familial Combined / Q000150:complications / Q000473:pathology; D006938:Hyperlipoproteinemia Type II / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D011817:Rabbits; D011973:Receptors, LDL / Q000235:genetics
D011973:Receptors, LDL; D001092:Arachidonate 12-Lipoxygenase; D001093:Arachidonate 15-Lipoxygenase; D003348:Cortisone